(Q34458090)

2 August 2017

1 reference

title

Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? (English)

1 reference

2 August 2017

0 references

1 reference

Nicholas J Brandon

2

0 references

author name string

John Dunlop

series ordinal

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

13 January 2015

1 reference

Journal of Psychopharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

29

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

230-238

1 reference

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

PET imaging shows loss of striatal PDE10A in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Modulation of N-methyl-D-aspartate receptor function by glycine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

De novo mutations in schizophrenia implicate synaptic networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Glycine transport inhibitors in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

PDE10A inhibitors: novel therapeutic drugs for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Schizophrenia and the alpha7 nicotinic acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Advances in targeting cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Update on typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Animal models of neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

A polygenic burden of rare disruptive mutations in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Future viable models of psychiatry drug discovery in pharma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxyli

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

5-HT(2C) agonists as therapeutics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Biological insights from 108 schizophrenia-associated genetic loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

A model of antipsychotic action in conditioned avoidance: a computational approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

Emerging biology of PDE10A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114565806

21 January 2018

Identifiers

DOI

10.1177/0269881114565806

1 reference

2 August 2017

1 reference